

Data Sheet

Plasmid #9

SKU No.: 20-0900

Description	TriAltus optimized Plasmid #9 for the expression of membrane proteins with C-terminal His8 and CL7 tags.
Expression	Transcription is induced with IPTG and driven by the T7 RNA polymerase. The plasmid is designed for expression in E. Coli.
Affinity Tag	The CL7 tag for purification is located at the C-terminus, downstream of a PreScission protease (PSC) cleavage site and His8 tag.
Cleavage Site(s)	Plasmid #9 includes a PSC cleavage site directly adjacent to the target protein and upstream of both the His8 and CL7 purification tags.
Other Tags	The plasmid contains a His8 tag located downstream of the target protein and cleavage tag but upstream of the CL7 tag.
Resistance	Kanamycin
Form	100 ng, dissolved in water.
Concentration	30 ng/μL
Stability	12 months after shipping
Storage	-20° C
Shipping	Room temperature

You can download the full protocol from <https://trialtusbioscience.com/products/#protocols>.

**For research use only.
 Not for diagnostic or therapeutic use.**

Licensing Information

TriAltus Bioscience holds the exclusive, worldwide license to the CL7 protein purification technology platform. It was licensed from the University of Alabama at Birmingham (UAB) in Birmingham, Alabama, USA. An international patent filing has been made with protection being sought in the United States, Europe, and other major markets. The CL7 purification technology is available for research use. For commercial use or resale, contact us at sales@trialtusbioscience.com to discuss commercial licensing.

Trademarks

The Company name, the terms "TriAltus" and "TriAltus Bioscience", the Company logo, and all related names, logos, product and service names, designs, and slogans are trademarks of the Company or its affiliates or licensors. You must not use such marks without the prior written permission of the Company. All other names, logos, product and service names, designs, and slogans on this Website are the trademarks of their respective owners.

Version: 1.0
 Revision Date: 11/20/2019